ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2312 • 2015 ACR/ARHP Annual Meeting

    Patient Preferences for Total Knee Replacement Surgery:  Two Year Follow-up  

    Ernest Vina1, Di Ran2, Erin Ashbeck2, Said Ibrahim3, Michael J. Hannon4, Jin Zhou5 and C. Kent Kwoh1, 1Rheumatology, University of Arizona, Tucson, AZ, 2Arthritis Center, University of Arizona, Tucson, AZ, 3Medicine, University of Pennsylvania, Philadelphia, PA, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5Epidemiology & Biostatistics, University of Arizona, Tucson, AZ

    Background/Purpose: Patients’ preferences for total knee replacement (TKR) may determine actual receipt of TKR and may also change over time.  Yet, no study has longitudinally…
  • Abstract Number: 2313 • 2015 ACR/ARHP Annual Meeting

    Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)

    Vibeke Strand1, Regina Rendas-Baum2, George J. Joseph3, Chieh-I Chen4, Hubert van Hoogstraten5, T. W. J. Huizinga6 and Mark C. Genovese7, 1Biopharmaceutical Consultant, Portola Valley, CA, 2QualityMetric Inc, Lincoln, RI, 3Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Sarilumab is a human monoclonal antibody (mAb) directed against the soluble IL-6 receptor (sIL-6R), administered subcutaneously (SC) every 2 weeks (q2w).  In the phase…
  • Abstract Number: 2314 • 2015 ACR/ARHP Annual Meeting

    Minimal Important Difference in HAQ: A Validation from Health Economic Perspectives in Patient with Rheumatoid Arthritis Using Real-World Data

    Chenglong Han1, Nan Li2 and Steven Peterson3, 1Outcomes Research, Janssen Global Services, LLC, Malvern, PA, 2Janssen Global Services, LLC, Spring House, PA, 3Janssen Global Services, LLC, Malvern, PA

    Background/Purpose: A change of 0.25 in HAQ score has been considered as clinically meaningful. This study is to evaluate the clinical meaningfulness of the HAQ…
  • Abstract Number: 2315 • 2015 ACR/ARHP Annual Meeting

    Six-Month Effects of a Multimedia Patient Education Tool in Patients with Rheumatoid Arthritis. a Randomized Controlled Trial

    Maria A. Lopez-Olivo1, Andrea Barbo2, Tara Rizvi3, Robert Volk4, Heather Lin5 and Maria E. Suarez-Almazor6, 1Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Rheumatology, Baylor College of Medicine, Houston, TX, 4Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, 5Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 6General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose: We conducted a multi-centered, open-label, parallel, randomized controlled trial to evaluate the efficacy of a multimedia-patient education tool (MM-PtET) for patients with rheumatoid arthritis…
  • Abstract Number: 2316 • 2015 ACR/ARHP Annual Meeting

    An Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic Naïve Rheumatoid Arthritis Patients

    Nicholas Kottak1, Melissa Rosenberg2, Dennis Parenti3 and Shelly Kafka3, 1Ethnographic Solutions, Washington, DC, 2Janssen Pharmaceuticals Inc, Horsham, PA, 3Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: To better understand how rheumatologists communicate the need to initiate biologic treatment and explain the risks and benefits, Janssen Pharmaceuticals initiated an ethnographic market…
  • Abstract Number: 2317 • 2015 ACR/ARHP Annual Meeting

    Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations

    Gary Crump1, James Bower2, Terrence Foley3, J. Timothy Harrington2, Nikita Hegde4, Drew Johnson5, Rafia Khalil6, Edmund LaCour7 and Robert Perhala8, 1Rheumatology Associates - Louisville, Louisville, KY, 2Joiner Associates LLC, Madison, WI, 3Terrence Foley MD Inc, Concord Twp, OH, 4Akron General Hospital, Cuyahoga Falls, OH, 5Crescendo Bioscience, Inc., South San Francisco, CA, 6Rafia Khalil Arthritis & Rheumatology Center, PC, Port Huron, MI, 7Dothan Medical Associates PC, Dothan, AL, 8University Hospitals, Cleveland, OH

    Background/Purpose: Accurate rheumatoid arthritis (RA) disease activity assessment is required for treatment consistent with Treat-to-Target (T2T) recommendations. Rheumatologists currently use a variety of patient-generated, physician-generated,…
  • Abstract Number: 2318 • 2015 ACR/ARHP Annual Meeting

    Inflammatory Arthritis Patient Perspectives on Strategies to Support Medication Adherence: A Qualitative Study Using a Novel Group Exercise

    Sharan K. Rai1, Pavandeep Mehat2, Anne Townsend3, Carlo Marra4, Harpreet Chhina5, Rhonda Shuckett6 and Mary A. De Vera2, 1Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 3Medical School, University of Exeter, Exeter, United Kingdom, 4School of Pharmacy, Memorial University, St. John's, NF, Canada, 5Orthopedic Surgery, BC Children's Hospital, Vancouver, BC, Canada, 6Rheumatology, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Disappointing and inconsistent findings of adherence intervention research in inflammatory arthritis (IA) highlight the need for further work in designing interventions that promote and…
  • Abstract Number: 2319 • 2015 ACR/ARHP Annual Meeting

    Mobile Medical Documentation of Patient-Reported-Outcome

    Jutta G. Richter1, Christina Kampling1, Gamal Chehab1, Hasan Acar1, Arnd Becker2, Meike Dieckert1 and Matthias Schneider1, 1Policlinic of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 2Ortenau Klinikum Offenburg-Gengenbach, Gengenbach, Gengenbach, Germany

    Background/Purpose: Mobile medical Applications (mApps) with integrated patient-reported outcome instruments (PROs) allow patients (pts) with rheumatoid arthritis (RA) self-monitoring and might strengthen self-management. Use of…
  • Abstract Number: 2320 • 2015 ACR/ARHP Annual Meeting

    The Use of Doppler Ultrasound in Patients with Rheumatoid Arthritis Improves Patient Understanding of Disease and Adherence to Treatment and Alters Clinical Practice

    Fred Joshua1, Christine Bailey2, Mona Marabani3, Evange Romas4, Raymond White3 and Peter Wong5, 1Combined Rheumatology Practice and Macquarie University, Sydney, Australia, 2AbbVie, Sydney, Australia, 3Private Rheumatology Practice, Sydney, Australia, 4Department of Medicine, University of Melbourne, Melbourne, Australia, 5Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia

    Background/Purpose: Doppler ultrasound (DUS) can detect subclinical joint inflammation and can be used to predict disease relapse or flare in patients with RA. The objectives…
  • Abstract Number: 2321 • 2015 ACR/ARHP Annual Meeting

    Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort

    Hélène Che1, Bernard Combe2, Jacques Morel3, Alain G. Cantagrel4, Laure Gossec5 and Cédric Lukas6, 1Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 2Rheumatology, Hopital Lapeyronie, Montpellier, France, 3Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 4Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 5Rheumatology, Pitié Salpetriere Hospital, Paris, France, 6Hopital Lapeyronie, Montpellier, France

    Background/Purpose: Activity of rheumatoid arthritis (RA) can be assessed by several outcome measures : joint counts, inflammatory syndrom but also auto-questionnaires such as global patient…
  • Abstract Number: 2323 • 2015 ACR/ARHP Annual Meeting

    Patient Priorities in Rheumatoid Arthritis (RA) Research: An Exploration of Patient Perspectives from Those Enrolled in an Ontario RA Cohort

    Laura Fullerton1, Angela Cesta2, Catherine Hoffstetter3 and Claire Bombardier2,4,5, 1Support, Systems and Outcomes, University Health Network, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3Patient partner, Toronto, ON, Canada, 4Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Patient experiences with rheumatoid arthritis (RA) symptoms, treatments, and rheumatology care are critically important for the assessment of treatment-effectiveness and quality of care for…
  • Abstract Number: 2324 • 2015 ACR/ARHP Annual Meeting

    Understanding the Importance of a Patient’s Role in the Management of RA: Results from a Patient-Based Survey

    Ara Dikranian1, James Galloway2, Jörn Kekow3, Anna Maniccia4, Dean Spurden5, Eustratios Bananis6, Allan Gibofsky7 and for the RA NarRAtives advisory panel, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Academic Department of Rheumatology, King´s College London, London, United Kingdom, 3University of Magdeburg, Magdeburg, Germany, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Tadworth, United Kingdom, 6Pfizer Inc, Collegeville, PA, 7Weill Cornell Medical College and Hospital for Special Surgery, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, debilitating condition for which there is no cure. The RA NarRAtive is a global initiative to identify patient…
  • Abstract Number: 2325 • 2015 ACR/ARHP Annual Meeting

    Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist

    Kathryn A. Gibson1, Katherine J. Bryant2 and Theodore Pincus3, 1Liverpool Hospital, Liverpool, Australia, 2University of New South Wales, Sydney, Australia, 3Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: A physician global estimate (DOCGL) is commonly used to assess patients with rheumatic diseases. Fibromyalgia (FM) has been reported as a comorbidity in 10-35%…
  • Abstract Number: 2326 • 2015 ACR/ARHP Annual Meeting

    Patient Preferences Regarding Route of Biologic Administration in an Inflammatory Arthritis Cohort

    Alysia Kwiatkowski1, Lucas Grisanti2, Joseph Grisanti3 and James Hatem4, 1Internal Medicine, Albany Medical Center, Albany, NY, 2Department of Biology, College of Wooster, Wooster, OH, 3Buffalo Rheumatology and Medicine, Orchard Park, NY, 4BioStatistics, Buffalo Rheumatology and Medicine, Orchard Park, NY

    Background/Purpose: Multiple biologic treatment modalities are available for managing systemic inflammatory disease states.  Patient preference regarding routes of administration is frequently unclear and has not…
  • Abstract Number: 2327 • 2015 ACR/ARHP Annual Meeting

    Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care

    Isabel Castrejón1, Annie Huang1, Sarah L. Everakes2, Ailda Nika1, Winston Sequeira1 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Internal Medicine, Rush University Medical Center, Chicago, IL

    Background/Purpose: RAPID3 is an index found on the MDHAQ, which is effective in rheumatoid arthritis (RA) clinical trials and clinical care (1). MDHAQ/RAPID3 also is…
  • « Previous Page
  • 1
  • …
  • 1841
  • 1842
  • 1843
  • 1844
  • 1845
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology